Patent intelligence · US
US 11364235
Method for treating cancer using a BCL-2 inhibitor in conjunction with an alpha-emitting radioimmunotherapeutic
Method for treating cancer using a BCL-2 inhibitor in conjunction with an alpha-emitting radioimmunotherapeutic
Patent details — US 11364235
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 21, 2022
- Expiration
- Jun 16, 2042
- Applicant
- Actinium Phamaceuticals, Inc.
- Claims
- 18
- CPC classes
- A61K, A61K2039/545, A61K31/496, A61K31/635
Quick answer
US 11364235 (Method for treating cancer using a BCL-2 inhibitor in conjunction with an alpha-emitting radioimmunotherapeutic) is held by Actinium Phamaceuticals, Inc.. Status: granted. Granted Jun 21, 2022. Expires Jun 16, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Actinium Phamaceuticals, Inc.
- Grant date
- Expiration
- Claims
- 18
- CPC classes
- A61K, A61K2039/545, A61K31/496, A61K31/635, A61K39/3955, A61K45/06
More from Actinium Phamaceuticals, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12410249
Low dose antibody-based methods for treating hematologic malignancies
granted -
US 12133849
Method for treating cancer using a BCL-2 inhibitor in conjunction with an alpha- emitting radioimmunotherapeutic
granted -
US 12083192
Methods for treatment of patients with myelodysplastic syndromes
granted -
US 11981741
Humanized anti-CD45 antibodies
granted -
US 11975081
Bifunctional chelators and conjugates
granted -
US 11964948
Bifunctional chelators and conjugates
granted -
US 11912780
Anti-CD45-based conditioning methods and uses thereof in conjunction with gene-edited cell-based therapies
granted -
US 11844799
Method for treating cancer using a BCL-2 inhibitor in conjunction with an alpha-emitting radioimmunotherapeutic
granted
Frequently asked questions
What is US patent 11364235?
US 11364235 (Method for treating cancer using a BCL-2 inhibitor in conjunction with an alpha-emitting radioimmunotherapeutic) is held by Actinium Phamaceuticals, Inc.. Status: granted. Granted Jun 21, 2022. Expires Jun 16, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11364235?
Actinium Phamaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 20 pharmaceutical patents for this assignee.
When does US 11364235 expire?
Our index shows an expiration date of Jun 16, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.